A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

Rami S. Komrokji, Hetty E. Carraway, Ulrich Germing, Martin Wermke, Amer M. Zeidan, Eric Fu, Björn Rüter, Ute Burkard, Annika Osswald, James M. Foran

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)2742-2747
Number of pages6
Issue number11
StatePublished - Nov 2022

ASJC Scopus subject areas

  • Hematology

Cite this